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Rewiring innate immune defence to eradicate cancer is one of the mechanisms of action of several 
monoclonal antibodies (mAbs) used in the clinic. Binding of mAbs onto a cell surface triggers antibody-
mediated effector killing by innate immune cells and through complement activation. As an alternative 
to mAbs, which face inherent issues with costs of production and stability, synthetic systems that can 
recruit endogenous antibodies from the blood stream to a cancer cell surface could be of great relevance. 
Here we explore antibody-recruiting polymers (ARPs) as a novel class of immunotherapy. ARPs consist 
of a cell binding motif linked to a polymer that contains multiple small molecule antibody-binding motifs 
along its backbone. As a proof of concept, we employ a lipid anchor that inserts into the phospholipid 
cell membrane and make use of a polymeric activated ester scaffold onto which we substitute 
dinitrophenol as antibody-binding motif. We demonstrate that ARPs allow for high avidity antibody 
binding and are able to drive antibody recruitment to treated cells for up to several days. Further we 
show that ARP-treated cancer cells are prone to antibody-mediated killing of cancer cells through 
phagocytosis by macrophages. 
Manuscript 
Exploiting innate immune effector mechanisms against the Fc domain of monoclonal antibodies (Abs) 
is gaining immense popularity in anti-cancer therapy and also holds promise for the treatment of 
infectious diseases.[1][2] Its mechanism of action relies on clustering of Abs onto a target (cancer) cell 
surface by binding with its Fab fragments to a protein expressed on the target cell surface. Subsequent 
exposure of the Fc domain[3] towards the external medium flags the cell for destruction by a combination 
of complement activation, NK-cell mediated killing and phagocytosis by macrophages.[4-6] The latter two 
mechanisms directly depend on recognition of Fc domains on the target cell surface by Fc receptors on 
the innate effector cells.[3] 
As an alternative to the use of externally administered monoclonal Abs, exploiting the presence of 
endogenous antibodies that are present in the serum of every human being,[7] could be beneficial as it 
circumvents the need for recombinant production and genetic engineering to make the Ab compatible 
with the host as well as avoiding stability issues often encountered with long term storage of mAbs. In 




recruit these to a target cell surface. The first question has been addressed by several groups and 
mainly focuses on the presence of antibodies in human blood against galactose--1,3-galactose, 
phosphorylcholine, rhamnose or dinitrophenol (DNP).[8] The nature of these endogenous antibodies 
varies from the consumption of meat (galactose--1,3-galactose), commensal bacteria in the gut 
(phosphorylcholine and rhamnose) and exposure to pesticides (DNP). The second question relates to 
antibody recruitment, which involves the process that drives binding of endogenous antibodies to a 
target cell surface. In this regard, hydrophobic interaction, which typically relies on a lipid motif 
conjugated to an antibody-binding motif, has been explored.[9] The lipid part anchors the cell membrane 
and exposes the antibody-binding motif to the external medium. This approach is intended for local 
application, i.e. by direct intratumoral injection, due to the lack in selectivity towards cancer cells. Another 
strategy involves conjugates composed of an antibody-binding motif and a target cell binding motif. For 
the latter, several cell surface receptors that are overexpressed by cancer cells have been explored, 
including the folate receptor,[10] PSMA,[11] uPAR,[12] and others. These approaches all involve mono- or 
at best bi-valent molecules, both on the level of the antibody-binding as well as the target cell binding 
motifs.  
The question we aim to address in this paper is whether polymeric scaffolds that contain multiple motifs 
of an antibody-recruiting motif allow for a more efficient antibody recruitment to the cell surface with 
prolonged cell surface persistence and efficient induction of innate effector killing. Hereto we explore 
the concept of so-called antibody-recruiting polymers (ARPs). These consist of multiple copies of on the 
one hand motifs that bind to endogenous antibodies and on the other hand a motif that anchors to the 
cell surface, thereby tagging the cell for attack by the innate immune system (Scheme 1).  
 
 
Scheme 1 Antibody-recruiting polymer (ARP) concept.  ARPs anchor to the cell surface by hydrophobic 
insertion of a lipid tail at the ARP chain end into the phospholipid cell membrane. Cell surface anchoring of ARPs 
triggers recruitment of endogenous antibodies to the cell, thereby flagging the cell for destruction by innate immune 





Scheme 2 Antibody-recruiting polymer (ARP) synthesis. A functionalized (i.e. biotin, cholesterol, monoalkyl- 
or dialkyl-lipid) chain transfer agent is used for RAFT polymerization of pentafluorophenyl acrylate followed by 
removal of the trithiocarbonate RAFT end group by treatment with an excess of ACVA. The polymer backbone is 
subsequently substituted with DNP antibody-recruiting motifs and 2-aminoethanol to render the polymer backbone 
hydrophilic. For fluorescent labeling rhodamine cadaverine is used. Control polymers are synthesized using a non-
functionalized chain transfer agent (HO*) and/or omitting DNP substitution. 
Whereas polymeric constructs that contain multiple hapten copies have been reported earlier,[13-14] it 
remains elusive whether these are capable to efficiently recruit endogenous antibodies to a cancer cell 
surface and trigger innate immune killing. Here we focus on ARPs bearing a lipid moiety at one of the 
chain ends that anchors to cell membranes through hydrophobic interaction. The therapeutic relevance 
of such ARPs lies within context of intratumoral injection where one aims to engineer the tumor 
microenvironment to become infiltrated with innate immune cells that induce effector killing. The thus 
created tumor debris can subsequently serve as a tumor antigen pool which offers opportunities to 
mount tumor-specific adaptive immunity to fight distal tumors as well as metastases. Of note, 
intratumoral administration also reduces the risks of unwanted systemic side reaction due to potential 
immunogenicity of multiple hapten copies onto a polymer backbone.  
To start, we focused on how to optimally design ARPs for antibody recruitment. Hereto, 
pentafluorophenyl acrylate (PFPA)[15] was polymerized by reversible addition-fragmentation chain 
transfer (RAFT),[16] targeting a final degree of polymerization (DP) of 100, followed by removal of the 
trithiocarbonate RAFT end-group by treatment with an excess of 4,4-azobis(4-cyanovaleric acid) 
(ACVA). For immobilization purpose (vide infra), a biotin-functionalized chain transfer agent (CTA) was 
used. Hereto, biotin was conjugated to 2,2′-(ethylenedioxy)diethylamine followed by conjugation to 2-
propanoic acid butyl trithiocarbonate (PABTC). The synthesis route of the polymers is depicted in 
Scheme 2 and the polymer properties are summarized in Table 1, showing narrow dispersity and thus 
good control over RAFT polymerization. Experimental characterization data are depicted in the 
Supporting Information section.  
Subsequently, biotin-polyPFPA was substituted with an amine-functionalized dinitrophenol (DNP) 
derivative (Scheme 2), targeting a degree of substitution (DS; amount of DNP motifs per 100 PFPA 
repeating units) of respectively 2, 5 and 10. To generate a hydrophilic polymer backbone, all unreacted 
PFP-esters were converted into hydrophilic repeating units by treatment of the polymer with an excess 
of 2-aminoethanol. UV-Vis analysis of the resulting polymers after purification revealed that the DNP 
content was in good agreement with the targeted DS. For comparison, we also synthesized a biotin-
polymer without DNP and a monovalent biotin-DNP compound by conjugating biotin to DNP via a 
diethylene glycol linker (cfr. Supporting Information for the synthesis route). Note that the reason for 
choosing DNP as antibody-recruiting motif in the context of this work was fostered by the commercial 
availability of anti-DNP antibodies, which strongly facilitates experimental readout compared to the use 
of full human serum as a source of endogenous antibodies.  
Biolayer interferometry (BLI) was used to investigate the influence of multiple DNP motifs on the avidity 
of the antibody binding. Hereto, streptavidin-coated sensors were loaded with the monovalent biotin-
DNP conjugate to test whether the chemistry used for conjugation still allows for antibody binding. When 




window for sensor loading and subsequent kinetic analysis (Figure S7) of anti-DNP binding, which was 
then used to measure the avidity of (polyclonal rabbit) anti-DNP binding to DNP-polymers. Figure 1 
shows sensorgrams of anti-DNP binding to DNP-polymer-functionalized sensors. These data 
demonstrate low non-specific antibody binding to control sensors loaded with control polymers that did 
not contain DNP. By contrast, DNP-polymers showed strong adsorption and low desorption of anti-DNP. 
Curve fitting and calculation of the binding avidity KD (Table 2), reveals a dramatic increase in binding 
avidity with increasing DS of DNP on the polymer backbone. Notably, more than a 4-log increase in KD 
of a DS 10 DNP-polymer compared to monovalent DNP is observed. This can likely be attributed to 
multivalent binding,[17] as once an antibody dissociates from one DNP motif, it can rapidly bind to a 
neighboring DNP motif located on the same or adjacent polymer backbone.  
 
Table 1 Characteristics of the synthesized polymers. 
Polymer DPtheo Conv.calc., a [%] DPcalc., b Mntheo, b [Da] Mnc [Da] Mwc [Da] ᴆ 
biotin-polyPFPA 110 89 98 23 800 15 200 20 100 1.32 
polyPFPA 100 85 85 20 400 13 200 15 400 1.18 
monoalkyl-polyPFPA 120 93 112 27 200 12 500 15 900 1.27 
dialkyl-polyPFPA 100 87 87 21 400 17 600 20 400 1.16 
cholesterol-polyPFPA 120 90 108 26 300 16 300 18 100 1.11 
a: conversion determined by 19F-NMR (282 MHz; CDCl3). 
b: based on conversion and molecular weight of monomer and CTA. 
c: determined by SEC (THF) 
 
 
Figure 1 Multivalency effect on antibody binding to ARPs. Biolayer interferometry sensorgrams of (polyclonal 
rabbit) anti-DNP binding to streptavidin-coated sensors functionalized with biotinylated polyDNP. A blank 
biotinylated polymer was used as a control to assess non-specific binding. A dilution series of 22.5, 11.25, 5.6, 2.8 
and 0 nM of anti-DNP was measured to calculate KD values. Sensors were dipped into the anti-DNP solution at the 
500 s time point, which marks the onset of adsorption. At the 1125 s time point (dotted line), sensors were dipped 




Table 2 Calculated KD values and KD error measured by biolayer interferometry (BLI).  
Ligand KD (M) KD error (M) 
biotin-DNP 1.12·10-8 3.18·10.11 
biotin-polyDNP DS2 1.23·10-10 2.73·10-12 
biotin-polyDNP DS5 6.80·10-11 2.54·10-12 
biotin-polyDNP DS10 < 1.00·10-12 < 1.00·10-12 
 
 
These findings prompted us to design ARPs based on a DP 100 polyPFPA backbone substituted with 
a DS 10 of DNP. As a proof-of-concept, we elaborated on ARPs that can anchor to the cell surface via 
hydrophobic insertion into the phospholipid cell membrane, inspired by earlier studies that 
macromolecular amphiphiles containing a lipid motif at their chain end are prone to spontaneous cell 
membrane anchoring.[18,19] Hereto we synthesized 3 different RAFT CTAs bearing respectively a 
monoalkyl, dialkyl and cholesterol motif (Scheme 2). In brief, a cholesterol-CTA was synthesized by 
simple esterification of cholesterol and PABTC. A mono-alkyl-CTA was synthesized by conjugation of 
stearyl chloride to aminopropanol followed by conjugation to PABTC. A dialkyl-CTA was synthesized by 
conjugating tetradecylamine to aspartic acid followed by conjugation to PABTC. Note that the choice for 
a 14 carbon alkyl chain was fostered by earlier reports suggesting that these show improved cell 
membrane anchoring relative to longer 18 carbon lipid tail based structures.[19] Lipid-CTAs were 
subsequently used for RAFT polymerization of polyPFPA, followed by DNP modification as detailed 
above for biotinylated polymers. Note that following trithiocarbonate end-group removal, the polymer 
was fluorescently labeled with tetramethylrhodamine-cadaverine (DS 1) to allow for detection by 
fluorescence-based techniques. The resulting polymer properties are summarized in Table 1, while 
experimental characterization is shown in the Supporting Information section. In all cases well defined 
narrowly dispersed polymers were obtained, pointing at good control over RAFT polymerization using 
these lipid-functionalized CTAs. 
To investigate the influence of the lipid tail on cell membrane anchoring, CT26 mouse colon cancer cells 
were pulsed in vitro with the lipid-polymer conjugates for 2h at 37 °C, followed by flow cytometry and 
confocal microscopy analysis. Note that in these experiments, the sample concentration was slightly 
adjusted based on the fluorescence emission intensity to ensure that the cells received equal doses of 
fluorescence as the latter parameter was used for quantification purpose. The mean fluorescence 
intensity (MFI; Figure 2A) values measured by flow cytometry indicated that all lipid-polymer conjugates 
anchor to cells, unlike the control polymer that lacks a lipid tail. These findings are confirmed by confocal 
microscopy showing the localization of the fluorescently labeled lipid-polymer conjugates at the cell 
surface. (Figure 2B) Interestingly, the dialkyl-polymer conjugate shows the highest extent of cellular 
association. Next, we investigated the ability of the lipid-polymer conjugates to recruit anti-DNP 
antibodies to the cell surface. Hereto, polymer-treated cells were washed to remove unbound polymer, 
and subsequently pulsed with AF488-labeled (polyclonal rabbit) anti-DNP followed by flow cytometry 
(Figure 2C) and confocal microscopy (Figure 2B) analysis. These data unambiguously demonstrate 
that only conjugates that contain both a lipid tail and DNP motifs are able to recruit anti-DNP to the cell 
surface. In accordance to the binding of the lipid-polymer conjugate itself, the dialkyl-containing 
construct is the most proficient in antibody recruitment. Importantly, control polymers that do not contain 
DNP motifs induce low non-specific binding in the same range as the autofluorescence of the cell. 
Furthermore, as shown in Figure 2D, a monovalent DNP-dialkyl lipid control conjugate (cfr. Scheme S1 
in supporting information for the chemical structure) had very poor anti-DNP recruiting capacity. This 
could be attributed to the DNP motif being buried too deep into the glycocalyx to allow for the anti-DNP 
to bind its target epitope, and because of the much lower avidity of anti-DNP towards monovalent DNP-
constructs relative to multivalent DNP-constructs as evidenced by biolayer interferometry (vide supra). 
In analogy with earlier reports by the Bertozzi group,[19] both dialkyl- and cholesterol-based ARP 




recruitment. Monoalkyl lipids have been reported to exhibit less efficient cell membrane anchoring, [20] 
likely due to their lower hydrophobicity and less structural similarity to lipid compounds in the cell 
membrane.[21] Cholesterol-based conjugates on their hand have been reported to undergo fast 
exchange from the cell membrane, which might account for the less efficient antibody-recruiting capacity 
of cholesterol-based ARPs.[22] Using the dialkyl-polyDNP conjugate, we subsequently tested its 
persistence on the cell surface over prolonged periods of time by treating cells with polymers followed 
by pulsing with anti-DNP at different time points prior to flow cytometry and confocal microscopy analysis. 
Note that in these experiments, cells were carefully washed to remove unbound polymer to avoid 
continuous replenishing of lipid-polymer on the cell surface from lipid-polymer in solution. These 
experiments (Figure 2E) demonstrate that for at least up to 4 days post dialkyl-polyDNP treatment, anti-
DNP can bind to the cell surface. Whereas antibody-dependent effector mechanisms occur fairly rapidly 
(vide infra for ADCP data), we hypothesize that prolonged cell surface display in vivo of ARPs allows for 
a higher chance of Fc-recognition to occur and innate effector killing to take place. Moreover, our data 
show that despite the fact that indeed ARPs become endocytosed to a certain extent (as evidenced by 
the dotted red fluorescent intracellular pattern in the confocal images in Figure 2B), a very significant 
fraction of ARPs remains on the cell surface and is capable of recruiting anti-DNP to the cell surface for 
up to 4 days post pulsing of cells with ARPs.   
 
 
Figure 2Antibody recruitment to ARP-treated cells. (A) Binding of ARPs through lipid-mediated anchoring to 
CT26 cells.(n=3; 1 way Anova **** : p<0,0001; *** : p<0,001; ** : p<0,0001) (B) Confocal microscopy images of 
cells treated with ARPs (red color) and anti-DNP (green color). Scale bar represents 10  m. (C) Antibody (anti-
DNP) recruitment to ARP-treated CT26 cells. Left panel shows a representative flow cytometry histogram of the 
dialkyl-polyDNP ARP with controls. Right panel compares all ARPs for their ability to recruit anti-DNP antibody to 
the surface of treated cells. (n=3; 1 way Anova **** : p<0,0001; *** : p<0,001; ** : p<0,0001) (D) Flow cytometry 
analysis comparing antibody recruiting capacity between a monovalent dialkyl-DNP conjugate and dialkyl-polyDNP. 
(n=3; 1 way Anova **** : p<0,0001) (E) Flow cytometry analysis of cell surface persistence of ARPs. Cells were 
treated with ARP and pulsed with anti-DNP at different time points. (n=3;  t test **** p<0,0001; *** : p<0,001). Note 




Interestingly, earlier reports suggest the cell surface persistence of dialkyl-polymer conjugates to be no 
more than 24h,[19,20] whereas at present we demonstrate antibody recruitment for at least 4 days on 
dialkyl-polyDNP treated cells. However, in these previous works, typically phospholipid-based 
conjugates where used whereas in our present work we make us of neutral charged amide-linked lipids. 
These findings highlight the complex influence of lipid-polymer amphiphile structure and membrane 
anchoring and internalization kinetics and the underlying pathways. Our data indicates that the dialkyl-
polyDNP conjugate was endocytosed, but at a rate that is sufficiently slow to still allow for antibody 
recruitment to last over several days. This could be a crucial feature in vivo to allow for prolonged 
exposure of ARP-treated tumors to antibody recruitment and subsequent innate immune attack. 
Moreover, our ARP strategy excels in simplicity and dialkyl-polyDNP does not require formulation into 
higher ordered structures such as fusionogenic liposomes to drive cell surface display.[23] 
As a final part of this work, we aimed at demonstrating the ability of ARPs to trigger cancer cell killing 
by innate effector immune cells. Hereto we performed a functional assay to analyze ARP- mediated 
phagocytosis (ADCP) by macrophages, triggered by Fc-receptor mediated recognition of clustered 
antibodies on the surface of an ARP-anchored cancer cell. Hereto we made use of A431 human 
squamous carcinoma cells and monoclonal human IgG1 anti-DNP to match species and because the 
IgG1 isotype is the most potent inducer of Fc-mediated effector killing in human.[4] Figure S8 in 
Supporting Information confirms that this antibody can also robustly be recruited onto the surface of 
ARP-treated cells.  
 
 
Figure 3 Innate effector killing of ARP-treated cells (A) Schematic illustration of the ADCP assay. A431 cancer 
cells are fluorescently labeled with eFluor450 (green color) and pulsed with polymer samples and monoclonal 
human IgG1 anti-DNP. Macrophages prepared from human peripheral blood monocytes (PBMCs) are fluorescently 
labeled with DiO (red color) and co-cultured for 4h with the treated cancer cells. (B) Phagocytosis of cancer cells 
by macrophages provokes a population of double positive cells in the upper right quadrant of flow cytometry scatter 
plot. (C) Quantification of ADCP efficiency by calculating the percentage of double positive cells in the upper right 
quadrant in the flow cytometry scatter plots in panel B (n=3). Cetuximab concentration was 10 ng/mL. (n=3; 1 way 




To assess ADCP, cells were pulsed with ARPs and anti-DNP, fluorescently labeled with eFluor 450 and 
co-cultured with macrophages prepared from human peripheral blood mononuclear cells (PBMCs), 
labeled with DiO. Flow cytometry analysis (Figure 3) clearly shows the presence of a double-positive 
quadrant, indicating phagocytosis of cancer cells by macrophages, only when cancer cells were treated 
with dialkyl-polyDNP ARP + anti-DNP. Controls that include lipid-polymer conjugates without DNP or 
without lipid only induce a low background phagocytosis. Note that the minor background phagocytosis 
caused by the lipid-poly control could be attributed to a slight extent of toxicity of this amphiphile, thereby 
triggering macrophage to clear dead/dying cells. 
Interestingly, ARPs induce a similar extent of phagocytosis as Cetuximab, a monoclonal antibody that 
recognizes the epidermal growth factor receptor (EGFR) which is strongly over-expressed by A431 cells 
and that is known to exert its mechanism of action through Fc-mediated innate effector killing. [4] The 
ability of ARPs, within a similar experimental context, to be equally potent as a  clinically effective drug 
highlights the potential of ARPs. Moreover, ARPs operate in a receptor-independent way, albeit 
requiring direct intratumoral injection when envisioning therapeutic translation.  
In summary, we have demonstrated the ability of polymer-lipid conjugates containing multiple DNP 
motifs to highly efficiently anchor to cell membranes and provoke robust recruitment of anti-DNP 
antibodies to the cell surface in a selective way. The antibody recruitment efficacy of polymeric 
constructs composed of multiple antibody-recruiting motifs dramatically surpasses control monovalent 
constructs. The feasibility of this approach was demonstrated to be highly efficient in vitro and proved 
capable to induce innate effector killing against ARP-treated cells. 
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